Erratum (Biological Psychiatry (2018) 83(1) (18–28), (S0006322317316189), (10.1016/j.biopsych.2017.05.016));Mechanistic Target of Rapamycin–Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model

Biological Psychiatry

Volumn 83, Issue 1, 2018, Pages 18-28

  Yang, Chun ^a   Ren, Qian ^a   Qu, Youge ^a   Zhang, Ji Chun ^a   Ma, Min ^a   Dong, Chao ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

(R) Ketamine; (S) Ketamine; Antidepressant; Enantiomer; ERK; mTOR

Indexed keywords

KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; AMINOACETONITRILE; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN REGION; CHRONIC SOCIAL DEFEAT STRESS; CHRONIC STRESS; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; ENANTIOMER; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; LOCOMOTION; MALE; MAPK SIGNALING; MOUSE; MTOR SIGNALING; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PSYCHOPHARMACOTHERAPY; SINGLE DRUG DOSE; SOCIAL INTERACTION TEST; SOCIAL STRESS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CHEMISTRY; CHRONIC DISEASE; DISEASE MODEL; DOMINANT-SUBORDINATE RELATIONSHIP; DRUG EFFECT; MENTAL STRESS; METABOLISM; SIGNAL TRANSDUCTION;

AMINOACETONITRILE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOMINANCE-SUBORDINATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; KETAMINE; MALE; MICE, INBRED C57BL; MORPHOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STRESS, PSYCHOLOGICAL; TOR SERINE-THREONINE KINASES;

EID: 85021105602     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2020.01.018     Document Type: Erratum

References (59)

1. Krystal, J.H., Sanacora, G., Duman, R.S., Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 73 (2013), 1133–1141.
2. Monteggia, L.M., Zarate, C. Jr., Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr Opin Neurobiol 30 (2015), 139–143.
3. Duman, R.S., Aghajanian, G.K., Sanacora, G., Krystal, J.H., Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22 (2016), 238–249.
4. Hashimoto, K., R-ketamine: A rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46 (2016), 2449–2451.
5. Hashimoto, K., Ketamine's antidepressant action: Beyond NMDA receptor inhibition. Expert Opin Ther Targets 173 (2016), 1389–1392.
6. Hashimoto, K., Rapid antidepressant activity of ketamine beyond NMDA receptor. Hashimoto, K., (eds.) The NMDA Receptors, 2017, Humana Press, New York, 69–81.
7. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
8. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
9. Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Green, C.E., Perez, A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 170 (2013), 1134–1142.
10. Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., Kronstein, P., Khalife, S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67 (2010), 793–802.
11. Zarate, C.A. Jr., Brutsche, N.E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71 (2012), 939–946.
12. Newport, D.J., Carpenter, L.L., McDonald, W.M., Potash, J.B., Tohen, M., Nemeroff, C.B., APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 172 (2015), 950–966.
13. Romeo, B., Choucha, W., Fossati, P., Rotge, J.Y., Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res 230 (2015), 682–688.
14. Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., et al. Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. Int J Neuropsychopharmacol, 19, 2016, pyv124.
15. Kishimoto, T., Chawla, J.M., Hagi, K., Zarate, C.A., Kane, J.M., Bauer, M., et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med 46 (2016), 1459–1472.
16. Diazgranados, N., Ibrahim, L.A., Brutsche, N.E., Ameli, R., Henter, I.D., Luckenbaugh, D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71 (2010), 1605–1611.
17. Price, R.B., Iosifescu, D.V., Murrough, J.W., Chang, L.C., Al Jurdi, R.K., Iqbal, S.Z., et al. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 31 (2014), 335–343.
18. Reinstatler, L., Youssef, N.A., Ketamine as a potential treatment for suicidal ideation: A systematic review of the literature. Drugs R D 15 (2015), 37–43.
19. Wilkinson, S.T., Sanacora, G., Ketamine: A potential rapid-acting antisuicidal agent?. Depress Anxiety 33 (2016), 711–717.
20. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994), 199–241.
21. Singh, J.B., Fedgchin, M., Daly, E.J., De Boer, P., Cooper, K., Lim, P., et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173 (2016), 816–826.
22. Newport, D.J., Schatzberg, A.F., Nemeroff, C.B., Whither ketamine as an antidepressant: panacea or toxin?. Depress Anxiety 33 (2016), 685–688.
23. Rush, A.J., Ketamine for treatment-resistant depression: Ready or not for clinical use?. Am J Psychiatry 170 (2013), 1079–1081.
24. Malhi, G.S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M.A., et al. Ketamine: Stimulating antidepressant treatment?. BJPsych Open 2 (2016), e5–e9.
25. Yang, C., Hashimoto, K., Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl) 231 (2014), 2041–2042.
26. Freedman, R., Further investigation of ketamine. Am J Psychiatry 173 (2016), 761–762.
27. Hashimoto, K., Detrimental side effects of repeated ketamine infusions in the brain. Am J Psychiatry 173 (2016), 1044–1045.
28. Zhu, W., Ding, Z., Zhang, Y., Shi, Y., Hashimoto, K., Lu, L., Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull 32 (2016), 557–564.
29. Sanacora, G., Frye, M.A., McDonald, W., Mathew, S.J., Turner, M.S., Schatzberg, A.F., et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74 (2017), 399–405.
30. Domino, E.F., Taming the ketamine tiger: 1965. Anesthesiology 113 (2010), 678–684.
31. Zhang, J.C., Li, S.X., Hashimoto, K., R(–)-Ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116 (2014), 137–141.
32. Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Yao, W., Ma, M., et al. R-Ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry, 5, 2015, e632.
33. Yang, C., Qu, Y., Abe, M., Nozawa, D., Chaki, S., Hashimoto, K., (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry 82 (2017), e43–e44.
34. Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.I., Hashimoto, K., et al. Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine. J Pharmacol Exp Ther 361 (2017), 9–16.
35. Shirayama, Y., Hashimoto, K., Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267 (2017), 177–182.
36. 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267 (2017), 173–176.
37. Yang, C., Han, M., Zhang, J.C., Ren, Q., Hashimoto, K., Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239 (2016), 281–283.
38. Yuan, K., Han, Y., Hashimoto, K., Lu, L., On the eve of upgrading antidepressants: (R)-Ketamine and its metabolites. Neurosci Bull 32 (2016), 565–568.
39. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
40. Duman, R.S., Aghajanian, G.A., Synaptic dysfunction in depression: Potential therapeutic targets. Science 338 (2012), 68–72.
41. Ohgi, Y., Futamura, T., Hashimoto, K., Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15 (2015), 206–221.
42. Koike, H., Iijima, M., Chaki, S., Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 61 (2011), 1419–1423.
43. Yang, C., Hu, Y.M., Zhou, Z.Q., Zhang, G.F., Yang, J.J., Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 118 (2013), 3–8.
44. Yang, C., Zhou, Z.Q., Gao, Z.Q., Shi, J.Y., Yang, J.J., Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol Psychiatry 73 (2013), e35–e36.
45. Zhou, W., Wang, N., Yang, C., Li, X.M., Zhou, Z.Q., Yang, J.J., Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 29 (2014), 419–423.
46. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
47. Cleary, C., Linde, J.A., Hiscock, K.M., Hadas, I., Belmaker, R.H., Agam, G., et al. Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull 76 (2008), 469–473.
48. Mendoza, M.C., Er, E.E., Blenis, J., The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36 (2011), 320–328.
49. Sawicka, K., Pyronneau, A., Chao, M., Bennett, M.V., Zukin, R.S., Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice. Proc Natl Acad Sci U S A 113 (2016), E6290–E6297.
50. Zhang, J.C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232 (2015), 4325–4335.
51. Yang, B., Zhang, J.C., Han, M., Yao, W., Yang, C., Ren, Q., et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 233 (2016), 3647–3657.
52. Chresta, C.M., Davies, B.R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S.E., et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70 (2010), 288–298.
53. Ren, Q., Ma, M., Ishima, T., Morisseau, C., Yang, J., Wagner, K.M., et al. Gene deciency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A 113 (2016), E1944–E1952.
54. Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69 (2011), 754–761.
55. Liu, X.L., Luo, L., Mu, R.H., Liu, B.B., Geng, D., Liu, Q., Yi, L.T., Fluoxetine regulates mTOR signaling in a region-dependent manner in depression-like mice. Sci Rep, 5, 2015, 16024.
56. Denk, M.C., Rewerts, C., Holsboer, F., Erhardt-Lehmann, A., Turck, C.W., Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry 168 (2011), 751–752.
57. Neasta, J., Barak, S., Hamada, S.B., Ron, D., mTOR complex 1: A key player in neuroadaptations induced by drugs of abuse. J Neurochem 130 (2014), 172–184.
58. Lepack, A., Bang, E., Lee, B., Dwyer, J.M., Duman, R.S., Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology 111 (2016), 242–252.
59. Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.